Capital World Investors
QNCX icon

Capital World Investors’s Quince Therapeutics QNCX Stock Holding History

Capital World Investors’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12,470
Closed -$15.4M – 584
2022
Q1 		$15.4M Sell
12,470
-39
-0.3% -$53.1K ﹤0.01% 505
2021
Q4 		$31.6M Sell
12,509
-4,926
-28% -$30.1M 0.01% 495
2021
Q3 		$320M Buy
17,435
+798
+5% +$12.7M 0.05% 257
2021
Q2 		$176M Buy
16,637
+12
+0.1% +$101K 0.03% 324
2021
Q1 		$120M Buy
16,625
+3,574
+27% +$25.7M 0.02% 345
2020
Q4 		$72.5M Buy
13,051
+24
+0.2% +$213K 0.01% 374
2020
Q3 		$130M Hold
13,027
– – 0.03% 310
2020
Q2 		$121M Buy
13,027
+9,310
+250% +$85.3M 0.03% 292
2020
Q1 		$33.9M Buy
3,717
+855
+30% +$8.44M 0.01% 358
2019
Q4 		$32.1M Buy
2,862
+1,570
+122% +$9.47M 0.01% 382
2019
Q3 		$6.44M Buy
+1,292
New +$7.95M ﹤0.01% 487

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $3.16B AUM 42.38% 1-Year Est. Return

Capital World Investors's QNCX Position: Q2 2022 in Review

Capital World Investors sold out of Quince Therapeutics (QNCX) in Q2 2022, closing a stake of 12,470 shares — an estimated $15.4M sold.

Capital World Investors first reported a position in QNCX in Q3 2019 and held it in 11 quarters. The position peaked at $320M in Q3 2021. 66 funds tracked by Wall St. Rank hold QNCX as of Q2 2022.

  • Capital World Investors reported no remaining Quince Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Capital World Investors sold 12,470 Quince Therapeutics shares in Q2 2022, an estimated $15.4M.
  • Capital World Investors first reported a position in Quince Therapeutics in Q3 2019 and held it in 11 quarters.
  • Capital World Investors's Quince Therapeutics position peaked at $320M in Q3 2021.
  • 66 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2022.

Based on Capital World Investors's 13F filing for Q2 2022, filed 15 Aug 2022.